Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bryant ranch prepack - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate ointment, 0.05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. halobetasol propionate ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ranbaxy laboratories inc. - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate 0.5 mg in 1 g

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ranbaxy laboratories inc. - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - halobetasol propionate 0.5 mg in 1 g

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bausch health us, llc - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - bryhali® (halobetasol propionate) lotion, 0.01% is indicated for the topical treatment of plaque psoriasis in adults. none. risk summary there are no available data on bryhali lotion use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, increased malformations, including cleft palate and omphalocele, were observed after oral administration of halobetasol propionate during organogenesis to pregnant rats and rabbits. the available data do not support relevant comparisons of systemic halobetasol propionate exposures achieved in the animal studies to exposures observed in humans after topical use of bryhali lotion. the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal dat

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

bausch health us, llc - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t), tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) - duobrii® (halobetasol propionate and tazarotene) lotion, 0.01%/0.045% is indicated for the topical treatment of plaque psoriasis in adults. duobrii lotion is contraindicated in pregnancy [see warnings and precautions (5.1), use in specific populations (8.1, 8.3)]. risk summary based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, duobrii lotion may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. safety in pregnant females has not been established. the potential risk to the fetus outweighs the potential benefit to the mother from duobrii lotion during pregnancy; therefore, duobrii lotion should be discontinued as soon as pregnancy is recognized [see contraindications (4), warnings and precautions (5.1), clinical pharmacology (12.3)] . observational studies suggest an increased risk of low birthweight in infants with the maternal use of potent or very potent topical corticosteroids (see data ).  in an

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

mayne pharma - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t) - lexette® is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. none. risk summary there are no available data on lexette use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. published data report an increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. in animal reproduction studies, increased malformations, including cleft palate and omphalocele, were observed after oral administration of halobetasol propionate during organogenesis to pregnant rats and rabbits. no comparisons of animal exposure with human exposure may be calculated due to minimal systemic exposure in humans after topical administration of lexette [see clinical pharmacology (12.3) ]. the background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated backgrou

Kenija - angļu - Pharmacy and Poisons Board

surgilinks ltd c/o yash pharma laboratories pvt.… p.o box 14461 - 00800, nairobi - halobetasol propionate usp - cream - halobetasol propionate usp 0.05 % - plain potent corticosteroids (group iii) for

Kenija - angļu - Pharmacy and Poisons Board

surgilinks ltd c/o yash pharma laboratories pvt.… p.o box 14461 - 00800, nairobi - halobetasol propionate usp + salicylic acid bp - cream - halobetasol propionate usp 0.05 % + salicylic… - ulobetasol

Kanāda - angļu - Health Canada

bausch health, canada inc. - halobetasol propionate - ointment - 0.05% - halobetasol propionate 0.05% - anti-inflammatory agents

Kanāda - angļu - Health Canada

bausch health, canada inc. - halobetasol propionate - cream - 0.05% - halobetasol propionate 0.05% - anti-inflammatory agents